Targets › YB1
1 program from 1 company in 5 trials: 4 Phase 2, 1 Phase 1; Oncology; next expected readout Apr 2027.
DNA- and RNA-binding protein involved in various processes, such as translational repression, RNA stabilization, mRNA splicing, DNA repair and transcription regulation. Predominantly acts as a RNA-binding protein: binds preferentially to the 5'-[CU]CUGCG-3' RNA motif and specifically recognizes mRNA transcripts modified by C5-methylcytosine (m5C). (UniProt, P67809)
Open in Phaseline: the race on YB1, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| University of Washington | CD105/Yb-1/SOX2/CDH3/MDM2-polyepitope Plasmid DNA Vaccine Plasmid DNA vaccine encoding multiple tumor-associated antigens (CD105/ENG, Yb-1/YBX1, SOX | ENG, YBX1, SOX2, CDH3, MDM2, CD105, YB1 | Phase 2 | Anatomic Stage IV Breast Cancer AJCC v8; Lung Non-Small Cell Carcinoma; Anatomic Stage IB Breast Cancer AJCC v8; HER2 Negative Breast Carcinoma | Apr 2027 |
Anatomic Stage IV Breast Cancer AJCC v8 (2) Lung Non-Small Cell Carcinoma (1) Anatomic Stage IB Breast Cancer AJCC v8 (1) HER2 Negative Breast Carcinoma (1)
mixed (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.